{"id":"W2599273184","doi":"10.1200/jco.2017.35.4_suppl.781","title":"Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; Cancer Care Ontario; Western University","funders":"","keywords":"Medicine; KRAS; Capecitabine; Internal medicine; Erlotinib; Clinical endpoint; Colorectal cancer; Oncology; Gastroenterology; Cancer; Phases of clinical research; Chemotherapy; Randomized controlled trial; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002823566,0.002164427,0.002522596,0.0004567137,0.0004562315,0.0009743562,0.001018361,0.001393851,0.005386854],"category_scores_gemma":[0.001459049,0.0008818692,0.001552114,0.0005949716,0.0009365446,0.0007653966,0.0003916171,0.002087852,0.001258221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00109018,"about_ca_system_score_gemma":0.001708946,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001355622,"about_ca_topic_score_gemma":0.003716158,"domain_scores_codex":[0.999324,0.0003783054,0.00003702032,0.0001093591,0.00005123911,0.0001001273],"domain_scores_gemma":[0.9990091,0.0001706804,0.0002499718,0.0001015364,0.00006824588,0.0004003986],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9675877,0.007934561,0.0025129,0.0004150005,0.0007672866,0.0001110545,0.00004435629,0.0005661362,0.004495546,0.00006834082,0.001165488,0.01433157],"study_design_scores_gemma":[0.9116611,0.08108597,0.004583293,0.00001847646,0.000459477,0.0001511951,0.00001481059,0.0005422628,0.0004789274,0.00008639799,0.0009063708,0.00001172224],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815302,0.004580493,0.0007929854,0.0008096852,0.0003261713,0.005999733,0.002997975,0.0001478121,0.002814902],"genre_scores_gemma":[0.9811481,0.00235156,0.001770789,0.001192716,0.0003229245,0.005021078,0.004476623,0.00003638486,0.003679857],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005386854,"threshold_uncertainty_score":0.01802087,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0557468869161804,"score_gpt":0.4607185790415015,"score_spread":0.4049716921253211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}